Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArtryaASX:AYA +8.60%22 3-Year EBITDA Growth Rate is 3.00% as of Dec. 2025, which is at its 10-year median of 3.00. GuruFocus rates ASX:AYA with a GF Score™ of 22/100. Among 526 Healthcare Providers & Services companies, Artrya ranks worse than 64.83% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Artrya was 3.00% per year. The lowest was 3.00% per year. And the median was 3.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Artrya 3-Year EBITDA Growth Rate Related Terms
ASX:AYA vs VEEV, BTSG, HQY: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Artrya's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artrya 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Artrya's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Artrya's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.00% mean?
Artrya (ASX:AYA) has a 3-Year EBITDA Growth Rate of 3.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Artrya and its competitors. This is near median its historical median of 3.00. Over the past decade, Artrya's 3-Year EBITDA Growth Rate has ranged from 3.00 to 3.00. According to the industry distribution chart, Artrya ranks #341 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 64.8%.
Is Artrya's 3-Year EBITDA Growth Rate too high?
Artrya's current 3-Year EBITDA Growth Rate of 3.00% is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 3.00. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Artrya's value of 3.00% is 70.6% below this industry median. Based on the distribution chart, Artrya ranks #341 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Artrya has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Artrya's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Artrya ranks #341 out of 526 companies for 3-Year EBITDA Growth Rate. This places Artrya in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Artrya's value of 3.00% is 70.6% below this benchmark. Historically, Artrya's own 3-Year EBITDA Growth Rate has ranged from 3.00 to 3.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 10.20, Artrya has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artrya's current 3-Year EBITDA Growth Rate of 3.00% is 70.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Artrya and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artrya's current 3-Year EBITDA Growth Rate is 3.00%, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artrya stock overvalued right now?
Artrya (ASX:AYA) has a current 3-Year EBITDA Growth Rate of 3.00%. The current 3-Year EBITDA Growth Rate is 3.00%, which is near median its 10-year median of 3.00 and 70.6% below the Healthcare Providers & Services industry median of 10.20. Artrya's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Artrya (ASX:AYA), the current 3-Year EBITDA Growth Rate is 3.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
22GF Score
Get the complete analysis for ASX:AYA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AYA has been successfully added to your 
